Bitnomial launches Injective futures in US, with eyes on ETF eligibility
The contracts mark Injective’s first entry into US-regulated derivatives markets and could help support a spot ETF following a filing from Canary Capital.
Chicago-based derivatives exchange Bitnomial has launched Injective (INJ) futures contracts, marking the first regulated derivatives trading for the blockchain protocol in the United States. The CFTC-regulated exchange began offering the futures products as part of its expanding digital asset derivatives portfolio.
This development represents Injective's debut in US-regulated derivatives markets, providing institutional and retail traders access to INJ exposure through traditional financial infrastructure. Injective operates as a blockchain built specifically for decentralized finance applications, focusing on derivatives trading and other financial products within the crypto ecosystem.
The launch carries significant implications for potential Injective exchange-traded fund development. Canary Capital recently filed for an Injective spot ETF with the Securities and Exchange Commission, and the availability of regulated futures contracts often serves as a prerequisite for ETF approval. The presence of CFTC-regulated derivatives can demonstrate market maturity and provide pricing mechanisms that regulators typically require before approving spot crypto ETFs.
Market participants will likely monitor trading volumes and institutional adoption of these Injective futures contracts, as strong performance could strengthen the case for eventual ETF approval. The development also reflects the broader trend of US exchanges expanding their crypto derivatives offerings amid growing institutional demand for regulated digital asset exposure.
Source: Cointelegraph
